|
|
| Acasti welcomes Dr Jean Davignon to its Scientific Advisory Board |
| Wednesday, January 26 2011 | |||||||
Neptune Technologies & Bioressources Inc. subsidiary Acasti Pharma Inc. welcomes Dr Jean Davignon to its Scientific Advisory Board World Renowned Clinician-Scientist and leading authority in the fields of Hyperlipidemia and Atherosclerosis
Laval,
Québec, CANADA – January 26, 2011 – Neptune Technologies & Bioressources Inc. (“Neptune”) (NASDAQ.NEPT - TSX.V.NTB) subsidiary Acasti Pharma Inc. (“Acasti”) are pleased to announce the expansion of Acasti’s Scientific Advisory Board (SAB) by welcoming Pr. Jean Davignon OC, GOQ, MD, MSc, FRCPC, FACP, FRSC, FACN, FAHA, FCAHS, to join Dr. Jacques Genest (McGill Univeristy), Dr. Steven Nissen (Cleveland Clinic), Pr. Ruth McPherson (University of Ottawa), Pr. William Harris (Sandford Research/USD), Pr. Thomas G. Hartman (Rutgers University Center) and Dr. Magdy M. Abdel-Malik (Quaestio Global Partners). Recipient of numerous awards and achievements from many outstanding organizations including the Markle Scholar in Academic Medicine (1967-1972), “Coeur Québec Or” from the Quebec Heart and Stroke Foundation and the FNG Starr Award of the Canadian Medical Association (1993). In 1995, Dr. Davignon was made an Officer of the Order of Canada, Canada's highest civilian honor. In 2006, he was made a Grand Officer of the National Order of Quebec; in 2000, he was awarded the Quebec Government's Prix Wilder-Penfield and in 1995, he was made a Fellow of the Royal Society of Canada. He also received a doctorate Honoris Causa from Université Paul Sabatier, Toulouse, France (1992), and the Grande Médaille d’Or du Centenaire from the Institut Pasteur of Lille, France (1994). The Jean Davignon Distinguished Cardiovascular and Metabolic Research Award, sponsored by Pfizer, was created in 2006. “Acasti Pharma continues to demonstrate its dedication to excellence by welcoming Dr. Jean Davignon, a world renowned clinician-scientist in the field Hyperlipidemia and Atherosclerosis” said Dr. Farhad Amiri, Director, Preclinical Studies, Acasti Pharma Inc. “We are honored to have the opportunity to work with Dr. Davignon and benefit both from his expertise and knowledge in the development of our multiple products currently in our pipeline” he added. “It is with great honor and respect that we welcome Dr. Jean Davignon as a member of our Scientific Advisory Board” said Dr. Tina Sampalis, President of Acasti Pharma Inc. “We are extremely proud to have attracted someone of the caliber of Dr. Davignon to our team completing the esteemed group of scientific experts guiding our efforts. Dr. Jean Davignon brings expertise on core aspects of Acasti’s product development” she added. “Overall, we have made considerable progress to date in Acasti; we are ready to initiate our first Phase II clinical study with CaPre™, Acasti’s drug candidate, while launching our first medical food Onemia™ in the United States and advancing on the commercialization of Acasti’s fixed dose combination over the counter product Vectos™” added Dr. Sampalis. “I am pleased and honored to join the scientific advisory board of Acasti Pharma Inc. as their drug development program is promising, at the leading-edge and raises many important mechanistic questions” commented Dr. Jean Davignon.
About
Neptune
Technologies & Bioressources Inc. Neptune is an
industry-recognized leader in the innovation, production and
formulation of science-based and clinically proven novel phospholipid
products for the nutraceutical and pharmaceutical markets. The
Company focuses on growing consumer health markets including
cardiovascular, inflammatory and neurological diseases driven by
consumers taking a more proactive approach to managing health and
preventing disease. The Company sponsors clinical trials aimed to
demonstrate its product health benefits and to obtain regulatory
approval for label health claims. Neptune is continuously expanding
its intellectual property portfolio as well as clinical studies and
regulatory approvals. Neptune’s products are marketed and
distributed in over 20 countries worldwide. Acasti Pharma is developing a product
portfolio of proprietary novel long-chain omega-3 phospholipids.
Phospholipids are the major component of cell membranes and are
essential for all vital cell processes. They are one of the
principal constituents of High Density Lipoprotein (good
cholesterol) and, as such, play an important role in modulating
cholesterol efflux. Acasti Pharma’s proprietary novel phospholipids
carry and functionalize the polyunsaturated omega-3 fatty acids EPA
and DHA, which have been shown to have substantial health benefits
and which are stabilized by potent antioxidants. Acasti Pharma is
focusing initially on treatments for chronic cardiovascular
conditions within the over-the-counter, medical food and
prescription drug markets. NeuroBioPharm
is pursuing pharmaceutical neurological applications, and a
clinical study for a medical food product with a multinational
partner is already initiated. The development of a prescription drug
candidate is currently in progress. Advanced clinical development
and commercialization is planned to be carried out with
multinational partners.
|
press releases
Investors Relations firms
Please contact the following Investors Relations firms :
CANADA
|
Mr. Bob Beaty Toll Free: 1-888-221-0915 +1 403 221.0915 [email protected] www.howardgroupinc.com |
USA
|
Mr. Dan Schustack 212 732.4300 [email protected] www.ceocast.com |
- TOLL-FREE (Canada-USA): 1-888-664-9166
- PHONE: 450 687-2262
- FAX: 450 687-2272
- EMAIL: [email protected]